Suppr超能文献

挖掘头颈部癌症肿瘤基因组:广泛存在的 PI3K-mTOR 通路改变和新的分子靶点。

Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.

机构信息

Oral and Pharyngeal Cancer Branch, National Institute of Dental Research, NIH, Bethesda, MD 20892-4330, USA.

出版信息

Cancer Discov. 2013 Jul;3(7):722-5. doi: 10.1158/2159-8290.CD-13-0239.

Abstract

Two studies published in this issue of Cancer Discovery describe the emerging mutational landscape of head and neck squamous cell carcinomas (HNSCC) and their genomic and epigenetic alterations, thus identifying novel actionable cancer drivers and predictive biomarkers for targeted therapies. Most genomic alterations in HNSCC converge in a handful of molecular pathways, resulting in cell-cycle deregulation, genomic instability, cell differentiation defects, and persistent mitogenic signaling, the latter involving aberrant phosphoinositide 3-kinase (PI3K)/mTOR pathway activation, thereby rendering HNSCC responsive to PI3K/mTOR inhibitors. Cancer Discov; 3(7); 722-5. ©2013 AACR.

摘要

本期《癌症发现》杂志发表的两项研究描述了头颈鳞状细胞癌(HNSCC)不断出现的突变特征及其基因组和表观遗传改变,从而确定了新型可操作的癌症驱动基因和针对靶向治疗的预测性生物标志物。HNSCC 中的大多数基因组改变都集中在少数几个分子途径中,导致细胞周期失调、基因组不稳定、细胞分化缺陷和持续的有丝分裂信号,后者涉及异常的磷酸肌醇 3-激酶(PI3K)/哺乳动物雷帕霉素靶蛋白(mTOR)途径激活,从而使 HNSCC 对 PI3K/mTOR 抑制剂敏感。Cancer Discov; 3(7); 722-5. ©2013 AACR.

相似文献

4
mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
Oncol Rep. 2011 Mar;25(3):763-8. doi: 10.3892/or.2011.1146. Epub 2011 Jan 14.
5
Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Expert Opin Ther Targets. 2015 Jun;19(6):795-805. doi: 10.1517/14728222.2015.1012157. Epub 2015 Feb 5.
6
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Oncotarget. 2017 Mar 28;8(13):22203-22217. doi: 10.18632/oncotarget.14729.
7
ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Oral Oncol. 2018 Sep;84:95-103. doi: 10.1016/j.oraloncology.2018.07.010. Epub 2018 Jul 27.
8
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.
Expert Opin Ther Targets. 2011 Jan;15(1):63-74. doi: 10.1517/14728222.2011.541440. Epub 2010 Nov 26.
10
Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Clin Cancer Res. 2015 Jun 15;21(12):2792-801. doi: 10.1158/1078-0432.CCR-14-3279. Epub 2015 Feb 27.

引用本文的文献

3
YAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution.
Nat Commun. 2025 Jan 8;16(1):498. doi: 10.1038/s41467-024-55660-6.
4
Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism.
Cancer Prev Res (Phila). 2024 Dec 3;17(12):571-583. doi: 10.1158/1940-6207.CAPR-24-0124.
6
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance.
Nat Cancer. 2024 Aug;5(8):1250-1266. doi: 10.1038/s43018-024-00781-6. Epub 2024 Jul 11.
9
YAP-Driven Malignant Reprogramming of Epithelial Stem Cells at Single Cell Resolution.
Res Sq. 2023 Oct 27:rs.3.rs-3426301. doi: 10.21203/rs.3.rs-3426301/v1.
10
New insights into RAS in head and neck cancer.
Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188963. doi: 10.1016/j.bbcan.2023.188963. Epub 2023 Aug 22.

本文引用的文献

1
PTEN deficiency contributes to the development and progression of head and neck cancer.
Neoplasia. 2013 May;15(5):461-71. doi: 10.1593/neo.121024.
2
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.
Cancer Discov. 2013 Jul;3(7):770-81. doi: 10.1158/2159-8290.CD-12-0537. Epub 2013 Apr 25.
3
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Cancer Discov. 2013 Jul;3(7):761-9. doi: 10.1158/2159-8290.CD-13-0103. Epub 2013 Apr 25.
4
Lessons from the cancer genome.
Cell. 2013 Mar 28;153(1):17-37. doi: 10.1016/j.cell.2013.03.002.
5
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
J Clin Oncol. 2013 Mar 20;31(9):e137-40. doi: 10.1200/JCO.2012.43.2716. Epub 2013 Jan 28.
6
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
7
mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.
Clin Cancer Res. 2012 May 1;18(9):2558-68. doi: 10.1158/1078-0432.CCR-11-2824. Epub 2012 Mar 12.
8
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Science. 2011 Aug 26;333(6046):1154-7. doi: 10.1126/science.1206923. Epub 2011 Jul 28.
9
The mutational landscape of head and neck squamous cell carcinoma.
Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.
10
The molecular biology of head and neck cancer.
Nat Rev Cancer. 2011 Jan;11(1):9-22. doi: 10.1038/nrc2982. Epub 2010 Dec 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验